Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade

Motley Fool2022-03-18

The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

487

Report

Comment（61）

Jazim
·2022-03-20
Okay
Reply
Like
Report
MugenQiang
·2022-03-20
Good
Reply
1
Report
Bank of Arai
·2022-03-19
Ok
Reply
2
Report
Cam20
·2022-03-19
[Grin] [Grin] [Grin] [Grin] [Grin] [Grin]
Reply
2
Report
Andrewcms
·2022-03-19
Yes
Reply
2
Report
Andrewcms
·2022-03-19
Like
Reply
2
Report
Sysy
·2022-03-19
Ol
Reply
2
Report
SSVC
·2022-03-19
K
Reply
2
Report
Kirton
·2022-03-19
Pharma stocks are always risky and they may one day just plunge to nothing if all their pipelines product fail... so many examples.
Reply
2
Report
FT585
·2022-03-19
Like
Reply
1
Report
Success88
·2022-03-19
Abbot milk powder
Reply
1
Report
titan86
·2022-03-19
Good insights
Reply
1
Report
Tmchoo
·2022-03-19
.
Reply
1
Report
WalkerWoon
·2022-03-19
Fly to the moon
Reply
1
Report
MamaLee
·2022-03-19
Ok
Reply
2
Report
Jess261
·2022-03-19
Okay
Reply
2
Report
HENRYCSC
·2022-03-19
Like pls
Reply
4
Report
leemoney
·2022-03-19
Nice
Reply
2
Report
ASMH
·2022-03-19
Like
Reply
3
Report
xuero
·2022-03-19
I don't think risking 450k (150k each) to make 550k (total 1 mil) in 10 years is attractive at all. Did I understand wrongly? [Thinking] [Doubt] [Glance] [Smug] [Speechless]
Reply
8
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2220711686?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-03-18 22:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2220711686","market":"us","top_or_hot":-1,"title":"Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade","media":"Motley Fool","content":"<div>\n<p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-18 22:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"辉瑞","start_time":0,"source_url":"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/","article_id":"2220711686","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2220711686","pubTimestamp":1647614760,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"As you approach your golden years, these companies could deliver the stability and growth that you need.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PFE":"辉瑞","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","ABT":"雅培","UNH":"联合健康","BK4082":"医疗保健设备","BK4535":"淡马锡持仓","BK4139":"生物科技","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4551":"寇图资本持仓","BK4581":"高盛持仓","BK4504":"桥水持仓","BNTX":"BioNTech SE","BK4154":"管理型保健护理","BK4548":"巴美列捷福持仓"},"translate_title":"想要一百万美元的退休生活？在这三只股票上投资15万美元，等待十年","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UNH":1,"PFE":1,"ABT":1,"BNTX":0.83},"content_text":"The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you're close to retirement.Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.1. PfizerPharmaceutical giant Pfizer (NYSE:PFE) has benefited from COVID-19 as one of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management's 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer's 2021 sales.Image source: Getty Images.However, the important part of this isn't the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer's nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer's growth efforts, even after its revenues from COVID-19 treatments fade.Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer's large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.2. Abbott LabsThe healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as AbbVie almost a decade ago. Today, Abbott Labs (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company's revenue growth has picked up, growing more than 15% annually over the past five years.This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today's share price, which results in low-double-digit total investment returns if the stock's valuation remains constant.3. UnitedHealth GroupHealth insurance company UnitedHealth Group (NYSE:UNH) is one of the world's largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It's likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company's dividend offers a yield of 1.1% as an added bonus for shareholders.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9034028116,"gmtCreate":1647738675901,"gmtModify":1676534261551,"author":{"id":"4091925166419540","authorId":"4091925166419540","name":"Jazim","avatar":"https://static.tigerbbs.com/85de7ecb80758afc3288fc8bb7e5ef27","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"4091925166419540","authorIdStr":"4091925166419540"},"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9034028116","repostId":2220711686,"repostType":4,"repost":{"id":"2220711686","pubTimestamp":1647614760,"share":"https://ttm.financial/m/news/2220711686?lang=&edition=fundamental","pubTime":"2022-03-18 22:46","market":"us","language":"en","title":"Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2220711686","media":"Motley Fool","summary":"As you approach your golden years, these companies could deliver the stability and growth that you need.","content":"<html><head></head><body><p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it&#39;s important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you&#39;re close to retirement.</p><p>Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.</p><h2>1. Pfizer</h2><p>Pharmaceutical giant <b>Pfizer</b> (NYSE:PFE) has benefited from COVID-19 as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management&#39;s 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer&#39;s 2021 sales.</p><p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F669475%2Fgettyimages-1316488076.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/><span>Image source: Getty Images.</span></p><p>However, the important part of this isn&#39;t the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer&#39;s nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer&#39;s growth efforts, even after its revenues from COVID-19 treatments fade.</p><p>Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer&#39;s large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.</p><h2>2. Abbott Labs</h2><p>The healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as <b>AbbVie</b> almost a decade ago. Today, <b>Abbott Labs</b> (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.</p><p>Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company&#39;s revenue growth has picked up, growing more than 15% annually over the past five years.</p><p>This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today&#39;s share price, which results in low-double-digit total investment returns if the stock&#39;s valuation remains constant.</p><h2>3. UnitedHealth Group</h2><p>Health insurance company <b>UnitedHealth Group</b> (NYSE:UNH) is one of the world&#39;s largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.</p><p>The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It&#39;s likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.</p><p>UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company&#39;s dividend offers a yield of 1.1% as an added bonus for shareholders.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-18 22:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4548":"巴美列捷福持仓","ABT":"雅培","BK4532":"文艺复兴科技持仓","UNH":"联合健康","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","BNTX":"BioNTech SE","BK4082":"医疗保健设备","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4154":"管理型保健护理","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4581":"高盛持仓"},"source_url":"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2220711686","content_text":"The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you're close to retirement.Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.1. PfizerPharmaceutical giant Pfizer (NYSE:PFE) has benefited from COVID-19 as one of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management's 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer's 2021 sales.Image source: Getty Images.However, the important part of this isn't the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer's nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer's growth efforts, even after its revenues from COVID-19 treatments fade.Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer's large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.2. Abbott LabsThe healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as AbbVie almost a decade ago. Today, Abbott Labs (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company's revenue growth has picked up, growing more than 15% annually over the past five years.This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today's share price, which results in low-double-digit total investment returns if the stock's valuation remains constant.3. UnitedHealth GroupHealth insurance company UnitedHealth Group (NYSE:UNH) is one of the world's largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It's likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company's dividend offers a yield of 1.1% as an added bonus for shareholders.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9034023360,"gmtCreate":1647738443359,"gmtModify":1676534261495,"author":{"id":"3576130746722228","authorId":"3576130746722228","name":"MugenQiang","avatar":"https://static.tigerbbs.com/f17ec4e89d68e2bc6ac39a336e9be71c","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":5,"crmLevelSwitch":0,"idStr":"3576130746722228","authorIdStr":"3576130746722228"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9034023360","repostId":2220711686,"repostType":4,"repost":{"id":"2220711686","pubTimestamp":1647614760,"share":"https://ttm.financial/m/news/2220711686?lang=&edition=fundamental","pubTime":"2022-03-18 22:46","market":"us","language":"en","title":"Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2220711686","media":"Motley Fool","summary":"As you approach your golden years, these companies could deliver the stability and growth that you need.","content":"<html><head></head><body><p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it&#39;s important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you&#39;re close to retirement.</p><p>Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.</p><h2>1. Pfizer</h2><p>Pharmaceutical giant <b>Pfizer</b> (NYSE:PFE) has benefited from COVID-19 as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management&#39;s 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer&#39;s 2021 sales.</p><p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F669475%2Fgettyimages-1316488076.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/><span>Image source: Getty Images.</span></p><p>However, the important part of this isn&#39;t the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer&#39;s nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer&#39;s growth efforts, even after its revenues from COVID-19 treatments fade.</p><p>Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer&#39;s large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.</p><h2>2. Abbott Labs</h2><p>The healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as <b>AbbVie</b> almost a decade ago. Today, <b>Abbott Labs</b> (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.</p><p>Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company&#39;s revenue growth has picked up, growing more than 15% annually over the past five years.</p><p>This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today&#39;s share price, which results in low-double-digit total investment returns if the stock&#39;s valuation remains constant.</p><h2>3. UnitedHealth Group</h2><p>Health insurance company <b>UnitedHealth Group</b> (NYSE:UNH) is one of the world&#39;s largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.</p><p>The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It&#39;s likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.</p><p>UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company&#39;s dividend offers a yield of 1.1% as an added bonus for shareholders.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-18 22:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4548":"巴美列捷福持仓","ABT":"雅培","BK4532":"文艺复兴科技持仓","UNH":"联合健康","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","BNTX":"BioNTech SE","BK4082":"医疗保健设备","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4154":"管理型保健护理","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4581":"高盛持仓"},"source_url":"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2220711686","content_text":"The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you're close to retirement.Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.1. PfizerPharmaceutical giant Pfizer (NYSE:PFE) has benefited from COVID-19 as one of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management's 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer's 2021 sales.Image source: Getty Images.However, the important part of this isn't the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer's nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer's growth efforts, even after its revenues from COVID-19 treatments fade.Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer's large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.2. Abbott LabsThe healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as AbbVie almost a decade ago. Today, Abbott Labs (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company's revenue growth has picked up, growing more than 15% annually over the past five years.This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today's share price, which results in low-double-digit total investment returns if the stock's valuation remains constant.3. UnitedHealth GroupHealth insurance company UnitedHealth Group (NYSE:UNH) is one of the world's largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It's likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company's dividend offers a yield of 1.1% as an added bonus for shareholders.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9035748704,"gmtCreate":1647703497539,"gmtModify":1676534259530,"author":{"id":"4099738254896670","authorId":"4099738254896670","name":"Bank of Arai","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4099738254896670","authorIdStr":"4099738254896670"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9035748704","repostId":2220711686,"repostType":4,"repost":{"id":"2220711686","pubTimestamp":1647614760,"share":"https://ttm.financial/m/news/2220711686?lang=&edition=fundamental","pubTime":"2022-03-18 22:46","market":"us","language":"en","title":"Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2220711686","media":"Motley Fool","summary":"As you approach your golden years, these companies could deliver the stability and growth that you need.","content":"<html><head></head><body><p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it&#39;s important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you&#39;re close to retirement.</p><p>Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.</p><h2>1. Pfizer</h2><p>Pharmaceutical giant <b>Pfizer</b> (NYSE:PFE) has benefited from COVID-19 as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management&#39;s 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer&#39;s 2021 sales.</p><p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F669475%2Fgettyimages-1316488076.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/><span>Image source: Getty Images.</span></p><p>However, the important part of this isn&#39;t the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer&#39;s nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer&#39;s growth efforts, even after its revenues from COVID-19 treatments fade.</p><p>Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer&#39;s large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.</p><h2>2. Abbott Labs</h2><p>The healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as <b>AbbVie</b> almost a decade ago. Today, <b>Abbott Labs</b> (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.</p><p>Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company&#39;s revenue growth has picked up, growing more than 15% annually over the past five years.</p><p>This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today&#39;s share price, which results in low-double-digit total investment returns if the stock&#39;s valuation remains constant.</p><h2>3. UnitedHealth Group</h2><p>Health insurance company <b>UnitedHealth Group</b> (NYSE:UNH) is one of the world&#39;s largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.</p><p>The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It&#39;s likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.</p><p>UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company&#39;s dividend offers a yield of 1.1% as an added bonus for shareholders.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-18 22:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4548":"巴美列捷福持仓","ABT":"雅培","BK4532":"文艺复兴科技持仓","UNH":"联合健康","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","BNTX":"BioNTech SE","BK4082":"医疗保健设备","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4154":"管理型保健护理","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4581":"高盛持仓"},"source_url":"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2220711686","content_text":"The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you're close to retirement.Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.1. PfizerPharmaceutical giant Pfizer (NYSE:PFE) has benefited from COVID-19 as one of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management's 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer's 2021 sales.Image source: Getty Images.However, the important part of this isn't the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer's nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer's growth efforts, even after its revenues from COVID-19 treatments fade.Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer's large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.2. Abbott LabsThe healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as AbbVie almost a decade ago. Today, Abbott Labs (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company's revenue growth has picked up, growing more than 15% annually over the past five years.This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today's share price, which results in low-double-digit total investment returns if the stock's valuation remains constant.3. UnitedHealth GroupHealth insurance company UnitedHealth Group (NYSE:UNH) is one of the world's largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It's likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company's dividend offers a yield of 1.1% as an added bonus for shareholders.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9035710075,"gmtCreate":1647677116681,"gmtModify":1676534258131,"author":{"id":"3586053412837856","authorId":"3586053412837856","name":"Cam20","avatar":"https://static.tigerbbs.com/037da9ce01a8e834173bfb42cccaa40f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586053412837856","authorIdStr":"3586053412837856"},"htmlText":"[Grin]&nbsp;[Grin]&nbsp;[Grin]&nbsp;[Grin]&nbsp;[Grin]&nbsp;[Grin]&nbsp;","listText":"[Grin]&nbsp;[Grin]&nbsp;[Grin]&nbsp;[Grin]&nbsp;[Grin]&nbsp;[Grin]&nbsp;","text":"[Grin] [Grin] [Grin] [Grin] [Grin] [Grin]","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9035710075","repostId":2220711686,"repostType":4,"repost":{"id":"2220711686","pubTimestamp":1647614760,"share":"https://ttm.financial/m/news/2220711686?lang=&edition=fundamental","pubTime":"2022-03-18 22:46","market":"us","language":"en","title":"Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2220711686","media":"Motley Fool","summary":"As you approach your golden years, these companies could deliver the stability and growth that you need.","content":"<html><head></head><body><p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it&#39;s important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you&#39;re close to retirement.</p><p>Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.</p><h2>1. Pfizer</h2><p>Pharmaceutical giant <b>Pfizer</b> (NYSE:PFE) has benefited from COVID-19 as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management&#39;s 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer&#39;s 2021 sales.</p><p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F669475%2Fgettyimages-1316488076.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/><span>Image source: Getty Images.</span></p><p>However, the important part of this isn&#39;t the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer&#39;s nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer&#39;s growth efforts, even after its revenues from COVID-19 treatments fade.</p><p>Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer&#39;s large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.</p><h2>2. Abbott Labs</h2><p>The healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as <b>AbbVie</b> almost a decade ago. Today, <b>Abbott Labs</b> (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.</p><p>Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company&#39;s revenue growth has picked up, growing more than 15% annually over the past five years.</p><p>This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today&#39;s share price, which results in low-double-digit total investment returns if the stock&#39;s valuation remains constant.</p><h2>3. UnitedHealth Group</h2><p>Health insurance company <b>UnitedHealth Group</b> (NYSE:UNH) is one of the world&#39;s largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.</p><p>The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It&#39;s likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.</p><p>UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company&#39;s dividend offers a yield of 1.1% as an added bonus for shareholders.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-18 22:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4548":"巴美列捷福持仓","ABT":"雅培","BK4532":"文艺复兴科技持仓","UNH":"联合健康","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","BNTX":"BioNTech SE","BK4082":"医疗保健设备","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4154":"管理型保健护理","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4581":"高盛持仓"},"source_url":"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2220711686","content_text":"The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you're close to retirement.Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.1. PfizerPharmaceutical giant Pfizer (NYSE:PFE) has benefited from COVID-19 as one of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management's 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer's 2021 sales.Image source: Getty Images.However, the important part of this isn't the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer's nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer's growth efforts, even after its revenues from COVID-19 treatments fade.Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer's large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.2. Abbott LabsThe healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as AbbVie almost a decade ago. Today, Abbott Labs (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company's revenue growth has picked up, growing more than 15% annually over the past five years.This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today's share price, which results in low-double-digit total investment returns if the stock's valuation remains constant.3. UnitedHealth GroupHealth insurance company UnitedHealth Group (NYSE:UNH) is one of the world's largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It's likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company's dividend offers a yield of 1.1% as an added bonus for shareholders.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9035790753,"gmtCreate":1647669123462,"gmtModify":1676534257640,"author":{"id":"4098421504436010","authorId":"4098421504436010","name":"Andrewcms","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":2,"crmLevelSwitch":0,"idStr":"4098421504436010","authorIdStr":"4098421504436010"},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9035790753","repostId":2220711686,"repostType":4,"repost":{"id":"2220711686","pubTimestamp":1647614760,"share":"https://ttm.financial/m/news/2220711686?lang=&edition=fundamental","pubTime":"2022-03-18 22:46","market":"us","language":"en","title":"Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2220711686","media":"Motley Fool","summary":"As you approach your golden years, these companies could deliver the stability and growth that you need.","content":"<html><head></head><body><p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it&#39;s important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you&#39;re close to retirement.</p><p>Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.</p><h2>1. Pfizer</h2><p>Pharmaceutical giant <b>Pfizer</b> (NYSE:PFE) has benefited from COVID-19 as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management&#39;s 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer&#39;s 2021 sales.</p><p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F669475%2Fgettyimages-1316488076.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/><span>Image source: Getty Images.</span></p><p>However, the important part of this isn&#39;t the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer&#39;s nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer&#39;s growth efforts, even after its revenues from COVID-19 treatments fade.</p><p>Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer&#39;s large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.</p><h2>2. Abbott Labs</h2><p>The healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as <b>AbbVie</b> almost a decade ago. Today, <b>Abbott Labs</b> (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.</p><p>Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company&#39;s revenue growth has picked up, growing more than 15% annually over the past five years.</p><p>This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today&#39;s share price, which results in low-double-digit total investment returns if the stock&#39;s valuation remains constant.</p><h2>3. UnitedHealth Group</h2><p>Health insurance company <b>UnitedHealth Group</b> (NYSE:UNH) is one of the world&#39;s largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.</p><p>The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It&#39;s likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.</p><p>UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company&#39;s dividend offers a yield of 1.1% as an added bonus for shareholders.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-18 22:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4548":"巴美列捷福持仓","ABT":"雅培","BK4532":"文艺复兴科技持仓","UNH":"联合健康","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","BNTX":"BioNTech SE","BK4082":"医疗保健设备","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4154":"管理型保健护理","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4581":"高盛持仓"},"source_url":"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2220711686","content_text":"The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you're close to retirement.Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.1. PfizerPharmaceutical giant Pfizer (NYSE:PFE) has benefited from COVID-19 as one of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management's 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer's 2021 sales.Image source: Getty Images.However, the important part of this isn't the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer's nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer's growth efforts, even after its revenues from COVID-19 treatments fade.Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer's large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.2. Abbott LabsThe healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as AbbVie almost a decade ago. Today, Abbott Labs (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company's revenue growth has picked up, growing more than 15% annually over the past five years.This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today's share price, which results in low-double-digit total investment returns if the stock's valuation remains constant.3. UnitedHealth GroupHealth insurance company UnitedHealth Group (NYSE:UNH) is one of the world's largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It's likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company's dividend offers a yield of 1.1% as an added bonus for shareholders.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9035707774,"gmtCreate":1647668871128,"gmtModify":1676534257617,"author":{"id":"4098421504436010","authorId":"4098421504436010","name":"Andrewcms","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":2,"crmLevelSwitch":0,"idStr":"4098421504436010","authorIdStr":"4098421504436010"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9035707774","repostId":2220711686,"repostType":4,"repost":{"id":"2220711686","pubTimestamp":1647614760,"share":"https://ttm.financial/m/news/2220711686?lang=&edition=fundamental","pubTime":"2022-03-18 22:46","market":"us","language":"en","title":"Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2220711686","media":"Motley Fool","summary":"As you approach your golden years, these companies could deliver the stability and growth that you need.","content":"<html><head></head><body><p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it&#39;s important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you&#39;re close to retirement.</p><p>Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.</p><h2>1. Pfizer</h2><p>Pharmaceutical giant <b>Pfizer</b> (NYSE:PFE) has benefited from COVID-19 as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management&#39;s 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer&#39;s 2021 sales.</p><p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F669475%2Fgettyimages-1316488076.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/><span>Image source: Getty Images.</span></p><p>However, the important part of this isn&#39;t the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer&#39;s nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer&#39;s growth efforts, even after its revenues from COVID-19 treatments fade.</p><p>Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer&#39;s large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.</p><h2>2. Abbott Labs</h2><p>The healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as <b>AbbVie</b> almost a decade ago. Today, <b>Abbott Labs</b> (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.</p><p>Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company&#39;s revenue growth has picked up, growing more than 15% annually over the past five years.</p><p>This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today&#39;s share price, which results in low-double-digit total investment returns if the stock&#39;s valuation remains constant.</p><h2>3. UnitedHealth Group</h2><p>Health insurance company <b>UnitedHealth Group</b> (NYSE:UNH) is one of the world&#39;s largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.</p><p>The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It&#39;s likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.</p><p>UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company&#39;s dividend offers a yield of 1.1% as an added bonus for shareholders.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-18 22:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4548":"巴美列捷福持仓","ABT":"雅培","BK4532":"文艺复兴科技持仓","UNH":"联合健康","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","BNTX":"BioNTech SE","BK4082":"医疗保健设备","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4154":"管理型保健护理","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4581":"高盛持仓"},"source_url":"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2220711686","content_text":"The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you're close to retirement.Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.1. PfizerPharmaceutical giant Pfizer (NYSE:PFE) has benefited from COVID-19 as one of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management's 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer's 2021 sales.Image source: Getty Images.However, the important part of this isn't the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer's nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer's growth efforts, even after its revenues from COVID-19 treatments fade.Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer's large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.2. Abbott LabsThe healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as AbbVie almost a decade ago. Today, Abbott Labs (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company's revenue growth has picked up, growing more than 15% annually over the past five years.This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today's share price, which results in low-double-digit total investment returns if the stock's valuation remains constant.3. UnitedHealth GroupHealth insurance company UnitedHealth Group (NYSE:UNH) is one of the world's largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It's likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company's dividend offers a yield of 1.1% as an added bonus for shareholders.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9035479162,"gmtCreate":1647663442995,"gmtModify":1676534257170,"author":{"id":"3581726174893746","authorId":"3581726174893746","name":"Sysy","avatar":"https://static.tigerbbs.com/f89400ba2f20ed80423858c0f6a3d8ee","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581726174893746","authorIdStr":"3581726174893746"},"htmlText":"Ol","listText":"Ol","text":"Ol","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9035479162","repostId":2220711686,"repostType":4,"repost":{"id":"2220711686","pubTimestamp":1647614760,"share":"https://ttm.financial/m/news/2220711686?lang=&edition=fundamental","pubTime":"2022-03-18 22:46","market":"us","language":"en","title":"Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2220711686","media":"Motley Fool","summary":"As you approach your golden years, these companies could deliver the stability and growth that you need.","content":"<html><head></head><body><p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it&#39;s important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you&#39;re close to retirement.</p><p>Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.</p><h2>1. Pfizer</h2><p>Pharmaceutical giant <b>Pfizer</b> (NYSE:PFE) has benefited from COVID-19 as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management&#39;s 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer&#39;s 2021 sales.</p><p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F669475%2Fgettyimages-1316488076.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/><span>Image source: Getty Images.</span></p><p>However, the important part of this isn&#39;t the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer&#39;s nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer&#39;s growth efforts, even after its revenues from COVID-19 treatments fade.</p><p>Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer&#39;s large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.</p><h2>2. Abbott Labs</h2><p>The healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as <b>AbbVie</b> almost a decade ago. Today, <b>Abbott Labs</b> (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.</p><p>Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company&#39;s revenue growth has picked up, growing more than 15% annually over the past five years.</p><p>This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today&#39;s share price, which results in low-double-digit total investment returns if the stock&#39;s valuation remains constant.</p><h2>3. UnitedHealth Group</h2><p>Health insurance company <b>UnitedHealth Group</b> (NYSE:UNH) is one of the world&#39;s largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.</p><p>The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It&#39;s likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.</p><p>UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company&#39;s dividend offers a yield of 1.1% as an added bonus for shareholders.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-18 22:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4548":"巴美列捷福持仓","ABT":"雅培","BK4532":"文艺复兴科技持仓","UNH":"联合健康","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","BNTX":"BioNTech SE","BK4082":"医疗保健设备","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4154":"管理型保健护理","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4581":"高盛持仓"},"source_url":"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2220711686","content_text":"The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you're close to retirement.Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.1. PfizerPharmaceutical giant Pfizer (NYSE:PFE) has benefited from COVID-19 as one of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management's 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer's 2021 sales.Image source: Getty Images.However, the important part of this isn't the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer's nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer's growth efforts, even after its revenues from COVID-19 treatments fade.Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer's large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.2. Abbott LabsThe healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as AbbVie almost a decade ago. Today, Abbott Labs (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company's revenue growth has picked up, growing more than 15% annually over the past five years.This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today's share price, which results in low-double-digit total investment returns if the stock's valuation remains constant.3. UnitedHealth GroupHealth insurance company UnitedHealth Group (NYSE:UNH) is one of the world's largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It's likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company's dividend offers a yield of 1.1% as an added bonus for shareholders.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9035446888,"gmtCreate":1647662252255,"gmtModify":1676534256937,"author":{"id":"3574906731000207","authorId":"3574906731000207","name":"SSVC","avatar":"https://static.tigerbbs.com/545a5ea462ff4ac7cc100bd3d8d97f72","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3574906731000207","authorIdStr":"3574906731000207"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9035446888","repostId":2220711686,"repostType":4,"repost":{"id":"2220711686","pubTimestamp":1647614760,"share":"https://ttm.financial/m/news/2220711686?lang=&edition=fundamental","pubTime":"2022-03-18 22:46","market":"us","language":"en","title":"Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2220711686","media":"Motley Fool","summary":"As you approach your golden years, these companies could deliver the stability and growth that you need.","content":"<html><head></head><body><p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it&#39;s important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you&#39;re close to retirement.</p><p>Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.</p><h2>1. Pfizer</h2><p>Pharmaceutical giant <b>Pfizer</b> (NYSE:PFE) has benefited from COVID-19 as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management&#39;s 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer&#39;s 2021 sales.</p><p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F669475%2Fgettyimages-1316488076.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/><span>Image source: Getty Images.</span></p><p>However, the important part of this isn&#39;t the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer&#39;s nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer&#39;s growth efforts, even after its revenues from COVID-19 treatments fade.</p><p>Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer&#39;s large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.</p><h2>2. Abbott Labs</h2><p>The healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as <b>AbbVie</b> almost a decade ago. Today, <b>Abbott Labs</b> (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.</p><p>Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company&#39;s revenue growth has picked up, growing more than 15% annually over the past five years.</p><p>This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today&#39;s share price, which results in low-double-digit total investment returns if the stock&#39;s valuation remains constant.</p><h2>3. UnitedHealth Group</h2><p>Health insurance company <b>UnitedHealth Group</b> (NYSE:UNH) is one of the world&#39;s largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.</p><p>The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It&#39;s likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.</p><p>UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company&#39;s dividend offers a yield of 1.1% as an added bonus for shareholders.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-18 22:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4548":"巴美列捷福持仓","ABT":"雅培","BK4532":"文艺复兴科技持仓","UNH":"联合健康","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","BNTX":"BioNTech SE","BK4082":"医疗保健设备","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4154":"管理型保健护理","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4581":"高盛持仓"},"source_url":"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2220711686","content_text":"The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you're close to retirement.Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.1. PfizerPharmaceutical giant Pfizer (NYSE:PFE) has benefited from COVID-19 as one of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management's 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer's 2021 sales.Image source: Getty Images.However, the important part of this isn't the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer's nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer's growth efforts, even after its revenues from COVID-19 treatments fade.Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer's large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.2. Abbott LabsThe healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as AbbVie almost a decade ago. Today, Abbott Labs (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company's revenue growth has picked up, growing more than 15% annually over the past five years.This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today's share price, which results in low-double-digit total investment returns if the stock's valuation remains constant.3. UnitedHealth GroupHealth insurance company UnitedHealth Group (NYSE:UNH) is one of the world's largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It's likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company's dividend offers a yield of 1.1% as an added bonus for shareholders.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9035443864,"gmtCreate":1647661699181,"gmtModify":1676534256850,"author":{"id":"3559451184746752","authorId":"3559451184746752","name":"Kirton","avatar":"https://static.tigerbbs.com/e41d69df3ca33182d7a527fc4f4ce0cb","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":8,"crmLevelSwitch":0,"idStr":"3559451184746752","authorIdStr":"3559451184746752"},"htmlText":"Pharma stocks are always risky and they may one day just plunge to nothing if all their pipelines product fail... so many examples.","listText":"Pharma stocks are always risky and they may one day just plunge to nothing if all their pipelines product fail... so many examples.","text":"Pharma stocks are always risky and they may one day just plunge to nothing if all their pipelines product fail... so many examples.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9035443864","repostId":2220711686,"repostType":4,"repost":{"id":"2220711686","pubTimestamp":1647614760,"share":"https://ttm.financial/m/news/2220711686?lang=&edition=fundamental","pubTime":"2022-03-18 22:46","market":"us","language":"en","title":"Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2220711686","media":"Motley Fool","summary":"As you approach your golden years, these companies could deliver the stability and growth that you need.","content":"<html><head></head><body><p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it&#39;s important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you&#39;re close to retirement.</p><p>Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.</p><h2>1. Pfizer</h2><p>Pharmaceutical giant <b>Pfizer</b> (NYSE:PFE) has benefited from COVID-19 as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management&#39;s 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer&#39;s 2021 sales.</p><p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F669475%2Fgettyimages-1316488076.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/><span>Image source: Getty Images.</span></p><p>However, the important part of this isn&#39;t the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer&#39;s nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer&#39;s growth efforts, even after its revenues from COVID-19 treatments fade.</p><p>Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer&#39;s large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.</p><h2>2. Abbott Labs</h2><p>The healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as <b>AbbVie</b> almost a decade ago. Today, <b>Abbott Labs</b> (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.</p><p>Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company&#39;s revenue growth has picked up, growing more than 15% annually over the past five years.</p><p>This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today&#39;s share price, which results in low-double-digit total investment returns if the stock&#39;s valuation remains constant.</p><h2>3. UnitedHealth Group</h2><p>Health insurance company <b>UnitedHealth Group</b> (NYSE:UNH) is one of the world&#39;s largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.</p><p>The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It&#39;s likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.</p><p>UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company&#39;s dividend offers a yield of 1.1% as an added bonus for shareholders.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-18 22:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4548":"巴美列捷福持仓","ABT":"雅培","BK4532":"文艺复兴科技持仓","UNH":"联合健康","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","BNTX":"BioNTech SE","BK4082":"医疗保健设备","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4154":"管理型保健护理","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4581":"高盛持仓"},"source_url":"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2220711686","content_text":"The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you're close to retirement.Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.1. PfizerPharmaceutical giant Pfizer (NYSE:PFE) has benefited from COVID-19 as one of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management's 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer's 2021 sales.Image source: Getty Images.However, the important part of this isn't the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer's nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer's growth efforts, even after its revenues from COVID-19 treatments fade.Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer's large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.2. Abbott LabsThe healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as AbbVie almost a decade ago. Today, Abbott Labs (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company's revenue growth has picked up, growing more than 15% annually over the past five years.This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today's share price, which results in low-double-digit total investment returns if the stock's valuation remains constant.3. UnitedHealth GroupHealth insurance company UnitedHealth Group (NYSE:UNH) is one of the world's largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It's likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company's dividend offers a yield of 1.1% as an added bonus for shareholders.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9035417492,"gmtCreate":1647654369418,"gmtModify":1676534255812,"author":{"id":"3562726241279787","authorId":"3562726241279787","name":"FT585","avatar":"https://static.tigerbbs.com/734b50619b12425294cb4715814bdedb","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3562726241279787","authorIdStr":"3562726241279787"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9035417492","repostId":2220711686,"repostType":4,"repost":{"id":"2220711686","pubTimestamp":1647614760,"share":"https://ttm.financial/m/news/2220711686?lang=&edition=fundamental","pubTime":"2022-03-18 22:46","market":"us","language":"en","title":"Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2220711686","media":"Motley Fool","summary":"As you approach your golden years, these companies could deliver the stability and growth that you need.","content":"<html><head></head><body><p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it&#39;s important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you&#39;re close to retirement.</p><p>Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.</p><h2>1. Pfizer</h2><p>Pharmaceutical giant <b>Pfizer</b> (NYSE:PFE) has benefited from COVID-19 as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management&#39;s 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer&#39;s 2021 sales.</p><p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F669475%2Fgettyimages-1316488076.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/><span>Image source: Getty Images.</span></p><p>However, the important part of this isn&#39;t the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer&#39;s nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer&#39;s growth efforts, even after its revenues from COVID-19 treatments fade.</p><p>Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer&#39;s large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.</p><h2>2. Abbott Labs</h2><p>The healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as <b>AbbVie</b> almost a decade ago. Today, <b>Abbott Labs</b> (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.</p><p>Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company&#39;s revenue growth has picked up, growing more than 15% annually over the past five years.</p><p>This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today&#39;s share price, which results in low-double-digit total investment returns if the stock&#39;s valuation remains constant.</p><h2>3. UnitedHealth Group</h2><p>Health insurance company <b>UnitedHealth Group</b> (NYSE:UNH) is one of the world&#39;s largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.</p><p>The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It&#39;s likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.</p><p>UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company&#39;s dividend offers a yield of 1.1% as an added bonus for shareholders.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-18 22:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4548":"巴美列捷福持仓","ABT":"雅培","BK4532":"文艺复兴科技持仓","UNH":"联合健康","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","BNTX":"BioNTech SE","BK4082":"医疗保健设备","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4154":"管理型保健护理","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4581":"高盛持仓"},"source_url":"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2220711686","content_text":"The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you're close to retirement.Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.1. PfizerPharmaceutical giant Pfizer (NYSE:PFE) has benefited from COVID-19 as one of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management's 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer's 2021 sales.Image source: Getty Images.However, the important part of this isn't the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer's nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer's growth efforts, even after its revenues from COVID-19 treatments fade.Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer's large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.2. Abbott LabsThe healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as AbbVie almost a decade ago. Today, Abbott Labs (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company's revenue growth has picked up, growing more than 15% annually over the past five years.This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today's share price, which results in low-double-digit total investment returns if the stock's valuation remains constant.3. UnitedHealth GroupHealth insurance company UnitedHealth Group (NYSE:UNH) is one of the world's largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It's likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company's dividend offers a yield of 1.1% as an added bonus for shareholders.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9035415923,"gmtCreate":1647653897281,"gmtModify":1676534255746,"author":{"id":"4101948424484190","authorId":"4101948424484190","name":"Success88","avatar":"https://static.itradeup.com/news/4408e1a22d73e99adb53aa65dde8ad91","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":4,"crmLevelSwitch":0,"idStr":"4101948424484190","authorIdStr":"4101948424484190"},"htmlText":"Abbot milk powder&nbsp;","listText":"Abbot milk powder&nbsp;","text":"Abbot milk powder","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9035415923","repostId":2220711686,"repostType":2,"repost":{"id":"2220711686","pubTimestamp":1647614760,"share":"https://ttm.financial/m/news/2220711686?lang=&edition=fundamental","pubTime":"2022-03-18 22:46","market":"us","language":"en","title":"Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2220711686","media":"Motley Fool","summary":"As you approach your golden years, these companies could deliver the stability and growth that you need.","content":"<html><head></head><body><p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it&#39;s important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you&#39;re close to retirement.</p><p>Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.</p><h2>1. Pfizer</h2><p>Pharmaceutical giant <b>Pfizer</b> (NYSE:PFE) has benefited from COVID-19 as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management&#39;s 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer&#39;s 2021 sales.</p><p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F669475%2Fgettyimages-1316488076.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/><span>Image source: Getty Images.</span></p><p>However, the important part of this isn&#39;t the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer&#39;s nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer&#39;s growth efforts, even after its revenues from COVID-19 treatments fade.</p><p>Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer&#39;s large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.</p><h2>2. Abbott Labs</h2><p>The healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as <b>AbbVie</b> almost a decade ago. Today, <b>Abbott Labs</b> (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.</p><p>Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company&#39;s revenue growth has picked up, growing more than 15% annually over the past five years.</p><p>This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today&#39;s share price, which results in low-double-digit total investment returns if the stock&#39;s valuation remains constant.</p><h2>3. UnitedHealth Group</h2><p>Health insurance company <b>UnitedHealth Group</b> (NYSE:UNH) is one of the world&#39;s largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.</p><p>The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It&#39;s likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.</p><p>UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company&#39;s dividend offers a yield of 1.1% as an added bonus for shareholders.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-18 22:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4548":"巴美列捷福持仓","ABT":"雅培","BK4532":"文艺复兴科技持仓","UNH":"联合健康","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","BNTX":"BioNTech SE","BK4082":"医疗保健设备","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4154":"管理型保健护理","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4581":"高盛持仓"},"source_url":"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2220711686","content_text":"The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you're close to retirement.Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.1. PfizerPharmaceutical giant Pfizer (NYSE:PFE) has benefited from COVID-19 as one of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management's 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer's 2021 sales.Image source: Getty Images.However, the important part of this isn't the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer's nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer's growth efforts, even after its revenues from COVID-19 treatments fade.Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer's large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.2. Abbott LabsThe healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as AbbVie almost a decade ago. Today, Abbott Labs (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company's revenue growth has picked up, growing more than 15% annually over the past five years.This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today's share price, which results in low-double-digit total investment returns if the stock's valuation remains constant.3. UnitedHealth GroupHealth insurance company UnitedHealth Group (NYSE:UNH) is one of the world's largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It's likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company's dividend offers a yield of 1.1% as an added bonus for shareholders.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9035438998,"gmtCreate":1647652334632,"gmtModify":1676534255429,"author":{"id":"4108088198062580","authorId":"4108088198062580","name":"titan86","avatar":"https://community-static.tradeup.com/news/eb15e08e7a175844747afe82c62273ea","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4108088198062580","authorIdStr":"4108088198062580"},"htmlText":"Good insights","listText":"Good insights","text":"Good insights","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9035438998","repostId":2220711686,"repostType":4,"repost":{"id":"2220711686","pubTimestamp":1647614760,"share":"https://ttm.financial/m/news/2220711686?lang=&edition=fundamental","pubTime":"2022-03-18 22:46","market":"us","language":"en","title":"Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2220711686","media":"Motley Fool","summary":"As you approach your golden years, these companies could deliver the stability and growth that you need.","content":"<html><head></head><body><p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it&#39;s important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you&#39;re close to retirement.</p><p>Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.</p><h2>1. Pfizer</h2><p>Pharmaceutical giant <b>Pfizer</b> (NYSE:PFE) has benefited from COVID-19 as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management&#39;s 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer&#39;s 2021 sales.</p><p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F669475%2Fgettyimages-1316488076.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/><span>Image source: Getty Images.</span></p><p>However, the important part of this isn&#39;t the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer&#39;s nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer&#39;s growth efforts, even after its revenues from COVID-19 treatments fade.</p><p>Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer&#39;s large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.</p><h2>2. Abbott Labs</h2><p>The healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as <b>AbbVie</b> almost a decade ago. Today, <b>Abbott Labs</b> (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.</p><p>Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company&#39;s revenue growth has picked up, growing more than 15% annually over the past five years.</p><p>This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today&#39;s share price, which results in low-double-digit total investment returns if the stock&#39;s valuation remains constant.</p><h2>3. UnitedHealth Group</h2><p>Health insurance company <b>UnitedHealth Group</b> (NYSE:UNH) is one of the world&#39;s largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.</p><p>The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It&#39;s likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.</p><p>UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company&#39;s dividend offers a yield of 1.1% as an added bonus for shareholders.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-18 22:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4548":"巴美列捷福持仓","ABT":"雅培","BK4532":"文艺复兴科技持仓","UNH":"联合健康","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","BNTX":"BioNTech SE","BK4082":"医疗保健设备","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4154":"管理型保健护理","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4581":"高盛持仓"},"source_url":"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2220711686","content_text":"The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you're close to retirement.Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.1. PfizerPharmaceutical giant Pfizer (NYSE:PFE) has benefited from COVID-19 as one of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management's 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer's 2021 sales.Image source: Getty Images.However, the important part of this isn't the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer's nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer's growth efforts, even after its revenues from COVID-19 treatments fade.Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer's large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.2. Abbott LabsThe healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as AbbVie almost a decade ago. Today, Abbott Labs (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company's revenue growth has picked up, growing more than 15% annually over the past five years.This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today's share price, which results in low-double-digit total investment returns if the stock's valuation remains constant.3. UnitedHealth GroupHealth insurance company UnitedHealth Group (NYSE:UNH) is one of the world's largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It's likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company's dividend offers a yield of 1.1% as an added bonus for shareholders.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9035433288,"gmtCreate":1647652199869,"gmtModify":1676534255388,"author":{"id":"3582279484837092","authorId":"3582279484837092","name":"Tmchoo","avatar":"https://static.tigerbbs.com/878e0bd104ad1fecaf17c2f1bce956fd","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":1,"crmLevelSwitch":0,"idStr":"3582279484837092","authorIdStr":"3582279484837092"},"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9035433288","repostId":2220711686,"repostType":4,"repost":{"id":"2220711686","pubTimestamp":1647614760,"share":"https://ttm.financial/m/news/2220711686?lang=&edition=fundamental","pubTime":"2022-03-18 22:46","market":"us","language":"en","title":"Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2220711686","media":"Motley Fool","summary":"As you approach your golden years, these companies could deliver the stability and growth that you need.","content":"<html><head></head><body><p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it&#39;s important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you&#39;re close to retirement.</p><p>Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.</p><h2>1. Pfizer</h2><p>Pharmaceutical giant <b>Pfizer</b> (NYSE:PFE) has benefited from COVID-19 as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management&#39;s 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer&#39;s 2021 sales.</p><p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F669475%2Fgettyimages-1316488076.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/><span>Image source: Getty Images.</span></p><p>However, the important part of this isn&#39;t the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer&#39;s nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer&#39;s growth efforts, even after its revenues from COVID-19 treatments fade.</p><p>Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer&#39;s large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.</p><h2>2. Abbott Labs</h2><p>The healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as <b>AbbVie</b> almost a decade ago. Today, <b>Abbott Labs</b> (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.</p><p>Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company&#39;s revenue growth has picked up, growing more than 15% annually over the past five years.</p><p>This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today&#39;s share price, which results in low-double-digit total investment returns if the stock&#39;s valuation remains constant.</p><h2>3. UnitedHealth Group</h2><p>Health insurance company <b>UnitedHealth Group</b> (NYSE:UNH) is one of the world&#39;s largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.</p><p>The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It&#39;s likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.</p><p>UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company&#39;s dividend offers a yield of 1.1% as an added bonus for shareholders.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-18 22:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4548":"巴美列捷福持仓","ABT":"雅培","BK4532":"文艺复兴科技持仓","UNH":"联合健康","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","BNTX":"BioNTech SE","BK4082":"医疗保健设备","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4154":"管理型保健护理","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4581":"高盛持仓"},"source_url":"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2220711686","content_text":"The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you're close to retirement.Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.1. PfizerPharmaceutical giant Pfizer (NYSE:PFE) has benefited from COVID-19 as one of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management's 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer's 2021 sales.Image source: Getty Images.However, the important part of this isn't the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer's nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer's growth efforts, even after its revenues from COVID-19 treatments fade.Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer's large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.2. Abbott LabsThe healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as AbbVie almost a decade ago. Today, Abbott Labs (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company's revenue growth has picked up, growing more than 15% annually over the past five years.This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today's share price, which results in low-double-digit total investment returns if the stock's valuation remains constant.3. UnitedHealth GroupHealth insurance company UnitedHealth Group (NYSE:UNH) is one of the world's largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It's likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company's dividend offers a yield of 1.1% as an added bonus for shareholders.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9035492842,"gmtCreate":1647651414819,"gmtModify":1676534255203,"author":{"id":"3567211702241491","authorId":"3567211702241491","name":"WalkerWoon","avatar":"https://static.tigerbbs.com/a772c81a4c88b39f7cdec13c1c0af077","vip":1,"crmLevel":5,"crmLevelSwitch":1,"idStr":"3567211702241491","authorIdStr":"3567211702241491"},"htmlText":"Fly to the moon&nbsp;","listText":"Fly to the moon&nbsp;","text":"Fly to the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9035492842","repostId":2220711686,"repostType":4,"repost":{"id":"2220711686","pubTimestamp":1647614760,"share":"https://ttm.financial/m/news/2220711686?lang=&edition=fundamental","pubTime":"2022-03-18 22:46","market":"us","language":"en","title":"Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2220711686","media":"Motley Fool","summary":"As you approach your golden years, these companies could deliver the stability and growth that you need.","content":"<html><head></head><body><p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it&#39;s important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you&#39;re close to retirement.</p><p>Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.</p><h2>1. Pfizer</h2><p>Pharmaceutical giant <b>Pfizer</b> (NYSE:PFE) has benefited from COVID-19 as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management&#39;s 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer&#39;s 2021 sales.</p><p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F669475%2Fgettyimages-1316488076.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/><span>Image source: Getty Images.</span></p><p>However, the important part of this isn&#39;t the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer&#39;s nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer&#39;s growth efforts, even after its revenues from COVID-19 treatments fade.</p><p>Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer&#39;s large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.</p><h2>2. Abbott Labs</h2><p>The healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as <b>AbbVie</b> almost a decade ago. Today, <b>Abbott Labs</b> (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.</p><p>Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company&#39;s revenue growth has picked up, growing more than 15% annually over the past five years.</p><p>This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today&#39;s share price, which results in low-double-digit total investment returns if the stock&#39;s valuation remains constant.</p><h2>3. UnitedHealth Group</h2><p>Health insurance company <b>UnitedHealth Group</b> (NYSE:UNH) is one of the world&#39;s largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.</p><p>The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It&#39;s likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.</p><p>UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company&#39;s dividend offers a yield of 1.1% as an added bonus for shareholders.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-18 22:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4548":"巴美列捷福持仓","ABT":"雅培","BK4532":"文艺复兴科技持仓","UNH":"联合健康","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","BNTX":"BioNTech SE","BK4082":"医疗保健设备","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4154":"管理型保健护理","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4581":"高盛持仓"},"source_url":"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2220711686","content_text":"The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you're close to retirement.Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.1. PfizerPharmaceutical giant Pfizer (NYSE:PFE) has benefited from COVID-19 as one of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management's 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer's 2021 sales.Image source: Getty Images.However, the important part of this isn't the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer's nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer's growth efforts, even after its revenues from COVID-19 treatments fade.Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer's large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.2. Abbott LabsThe healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as AbbVie almost a decade ago. Today, Abbott Labs (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company's revenue growth has picked up, growing more than 15% annually over the past five years.This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today's share price, which results in low-double-digit total investment returns if the stock's valuation remains constant.3. UnitedHealth GroupHealth insurance company UnitedHealth Group (NYSE:UNH) is one of the world's largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It's likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company's dividend offers a yield of 1.1% as an added bonus for shareholders.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9035496009,"gmtCreate":1647651261790,"gmtModify":1676534255163,"author":{"id":"3579998898288031","authorId":"3579998898288031","name":"MamaLee","avatar":"https://static.tigerbbs.com/3b65143242ad70cd231ddce7436fdb25","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":5,"crmLevelSwitch":1,"idStr":"3579998898288031","authorIdStr":"3579998898288031"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9035496009","repostId":2220711686,"repostType":4,"repost":{"id":"2220711686","pubTimestamp":1647614760,"share":"https://ttm.financial/m/news/2220711686?lang=&edition=fundamental","pubTime":"2022-03-18 22:46","market":"us","language":"en","title":"Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2220711686","media":"Motley Fool","summary":"As you approach your golden years, these companies could deliver the stability and growth that you need.","content":"<html><head></head><body><p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it&#39;s important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you&#39;re close to retirement.</p><p>Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.</p><h2>1. Pfizer</h2><p>Pharmaceutical giant <b>Pfizer</b> (NYSE:PFE) has benefited from COVID-19 as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management&#39;s 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer&#39;s 2021 sales.</p><p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F669475%2Fgettyimages-1316488076.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/><span>Image source: Getty Images.</span></p><p>However, the important part of this isn&#39;t the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer&#39;s nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer&#39;s growth efforts, even after its revenues from COVID-19 treatments fade.</p><p>Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer&#39;s large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.</p><h2>2. Abbott Labs</h2><p>The healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as <b>AbbVie</b> almost a decade ago. Today, <b>Abbott Labs</b> (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.</p><p>Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company&#39;s revenue growth has picked up, growing more than 15% annually over the past five years.</p><p>This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today&#39;s share price, which results in low-double-digit total investment returns if the stock&#39;s valuation remains constant.</p><h2>3. UnitedHealth Group</h2><p>Health insurance company <b>UnitedHealth Group</b> (NYSE:UNH) is one of the world&#39;s largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.</p><p>The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It&#39;s likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.</p><p>UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company&#39;s dividend offers a yield of 1.1% as an added bonus for shareholders.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-18 22:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4548":"巴美列捷福持仓","ABT":"雅培","BK4532":"文艺复兴科技持仓","UNH":"联合健康","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","BNTX":"BioNTech SE","BK4082":"医疗保健设备","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4154":"管理型保健护理","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4581":"高盛持仓"},"source_url":"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2220711686","content_text":"The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you're close to retirement.Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.1. PfizerPharmaceutical giant Pfizer (NYSE:PFE) has benefited from COVID-19 as one of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management's 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer's 2021 sales.Image source: Getty Images.However, the important part of this isn't the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer's nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer's growth efforts, even after its revenues from COVID-19 treatments fade.Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer's large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.2. Abbott LabsThe healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as AbbVie almost a decade ago. Today, Abbott Labs (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company's revenue growth has picked up, growing more than 15% annually over the past five years.This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today's share price, which results in low-double-digit total investment returns if the stock's valuation remains constant.3. UnitedHealth GroupHealth insurance company UnitedHealth Group (NYSE:UNH) is one of the world's largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It's likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company's dividend offers a yield of 1.1% as an added bonus for shareholders.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9035408577,"gmtCreate":1647649815071,"gmtModify":1676534254857,"author":{"id":"3586490638953193","authorId":"3586490638953193","name":"Jess261","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3586490638953193","authorIdStr":"3586490638953193"},"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9035408577","repostId":2220711686,"repostType":4,"repost":{"id":"2220711686","pubTimestamp":1647614760,"share":"https://ttm.financial/m/news/2220711686?lang=&edition=fundamental","pubTime":"2022-03-18 22:46","market":"us","language":"en","title":"Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2220711686","media":"Motley Fool","summary":"As you approach your golden years, these companies could deliver the stability and growth that you need.","content":"<html><head></head><body><p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it&#39;s important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you&#39;re close to retirement.</p><p>Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.</p><h2>1. Pfizer</h2><p>Pharmaceutical giant <b>Pfizer</b> (NYSE:PFE) has benefited from COVID-19 as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management&#39;s 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer&#39;s 2021 sales.</p><p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F669475%2Fgettyimages-1316488076.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/><span>Image source: Getty Images.</span></p><p>However, the important part of this isn&#39;t the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer&#39;s nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer&#39;s growth efforts, even after its revenues from COVID-19 treatments fade.</p><p>Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer&#39;s large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.</p><h2>2. Abbott Labs</h2><p>The healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as <b>AbbVie</b> almost a decade ago. Today, <b>Abbott Labs</b> (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.</p><p>Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company&#39;s revenue growth has picked up, growing more than 15% annually over the past five years.</p><p>This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today&#39;s share price, which results in low-double-digit total investment returns if the stock&#39;s valuation remains constant.</p><h2>3. UnitedHealth Group</h2><p>Health insurance company <b>UnitedHealth Group</b> (NYSE:UNH) is one of the world&#39;s largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.</p><p>The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It&#39;s likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.</p><p>UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company&#39;s dividend offers a yield of 1.1% as an added bonus for shareholders.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-18 22:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4548":"巴美列捷福持仓","ABT":"雅培","BK4532":"文艺复兴科技持仓","UNH":"联合健康","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","BNTX":"BioNTech SE","BK4082":"医疗保健设备","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4154":"管理型保健护理","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4581":"高盛持仓"},"source_url":"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2220711686","content_text":"The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you're close to retirement.Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.1. PfizerPharmaceutical giant Pfizer (NYSE:PFE) has benefited from COVID-19 as one of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management's 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer's 2021 sales.Image source: Getty Images.However, the important part of this isn't the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer's nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer's growth efforts, even after its revenues from COVID-19 treatments fade.Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer's large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.2. Abbott LabsThe healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as AbbVie almost a decade ago. Today, Abbott Labs (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company's revenue growth has picked up, growing more than 15% annually over the past five years.This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today's share price, which results in low-double-digit total investment returns if the stock's valuation remains constant.3. UnitedHealth GroupHealth insurance company UnitedHealth Group (NYSE:UNH) is one of the world's largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It's likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company's dividend offers a yield of 1.1% as an added bonus for shareholders.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9035576832,"gmtCreate":1647648918709,"gmtModify":1676534254616,"author":{"id":"3575091428590185","authorId":"3575091428590185","name":"HENRYCSC","avatar":"https://static.tigerbbs.com/6d47a6dec25b21dc547a5b982674c499","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575091428590185","authorIdStr":"3575091428590185"},"htmlText":"Like pls&nbsp;","listText":"Like pls&nbsp;","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9035576832","repostId":2220711686,"repostType":4,"repost":{"id":"2220711686","pubTimestamp":1647614760,"share":"https://ttm.financial/m/news/2220711686?lang=&edition=fundamental","pubTime":"2022-03-18 22:46","market":"us","language":"en","title":"Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2220711686","media":"Motley Fool","summary":"As you approach your golden years, these companies could deliver the stability and growth that you need.","content":"<html><head></head><body><p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it&#39;s important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you&#39;re close to retirement.</p><p>Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.</p><h2>1. Pfizer</h2><p>Pharmaceutical giant <b>Pfizer</b> (NYSE:PFE) has benefited from COVID-19 as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management&#39;s 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer&#39;s 2021 sales.</p><p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F669475%2Fgettyimages-1316488076.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/><span>Image source: Getty Images.</span></p><p>However, the important part of this isn&#39;t the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer&#39;s nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer&#39;s growth efforts, even after its revenues from COVID-19 treatments fade.</p><p>Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer&#39;s large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.</p><h2>2. Abbott Labs</h2><p>The healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as <b>AbbVie</b> almost a decade ago. Today, <b>Abbott Labs</b> (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.</p><p>Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company&#39;s revenue growth has picked up, growing more than 15% annually over the past five years.</p><p>This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today&#39;s share price, which results in low-double-digit total investment returns if the stock&#39;s valuation remains constant.</p><h2>3. UnitedHealth Group</h2><p>Health insurance company <b>UnitedHealth Group</b> (NYSE:UNH) is one of the world&#39;s largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.</p><p>The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It&#39;s likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.</p><p>UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company&#39;s dividend offers a yield of 1.1% as an added bonus for shareholders.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-18 22:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4548":"巴美列捷福持仓","ABT":"雅培","BK4532":"文艺复兴科技持仓","UNH":"联合健康","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","BNTX":"BioNTech SE","BK4082":"医疗保健设备","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4154":"管理型保健护理","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4581":"高盛持仓"},"source_url":"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2220711686","content_text":"The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you're close to retirement.Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.1. PfizerPharmaceutical giant Pfizer (NYSE:PFE) has benefited from COVID-19 as one of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management's 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer's 2021 sales.Image source: Getty Images.However, the important part of this isn't the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer's nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer's growth efforts, even after its revenues from COVID-19 treatments fade.Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer's large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.2. Abbott LabsThe healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as AbbVie almost a decade ago. Today, Abbott Labs (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company's revenue growth has picked up, growing more than 15% annually over the past five years.This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today's share price, which results in low-double-digit total investment returns if the stock's valuation remains constant.3. UnitedHealth GroupHealth insurance company UnitedHealth Group (NYSE:UNH) is one of the world's largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It's likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company's dividend offers a yield of 1.1% as an added bonus for shareholders.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9035544353,"gmtCreate":1647648125002,"gmtModify":1676534254435,"author":{"id":"3573369274290933","authorId":"3573369274290933","name":"leemoney","avatar":"https://static.tigerbbs.com/f6a1151f25a904ba29b93dd84a40bb5a","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3573369274290933","authorIdStr":"3573369274290933"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9035544353","repostId":2220711686,"repostType":4,"repost":{"id":"2220711686","pubTimestamp":1647614760,"share":"https://ttm.financial/m/news/2220711686?lang=&edition=fundamental","pubTime":"2022-03-18 22:46","market":"us","language":"en","title":"Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2220711686","media":"Motley Fool","summary":"As you approach your golden years, these companies could deliver the stability and growth that you need.","content":"<html><head></head><body><p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it&#39;s important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you&#39;re close to retirement.</p><p>Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.</p><h2>1. Pfizer</h2><p>Pharmaceutical giant <b>Pfizer</b> (NYSE:PFE) has benefited from COVID-19 as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management&#39;s 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer&#39;s 2021 sales.</p><p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F669475%2Fgettyimages-1316488076.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/><span>Image source: Getty Images.</span></p><p>However, the important part of this isn&#39;t the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer&#39;s nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer&#39;s growth efforts, even after its revenues from COVID-19 treatments fade.</p><p>Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer&#39;s large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.</p><h2>2. Abbott Labs</h2><p>The healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as <b>AbbVie</b> almost a decade ago. Today, <b>Abbott Labs</b> (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.</p><p>Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company&#39;s revenue growth has picked up, growing more than 15% annually over the past five years.</p><p>This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today&#39;s share price, which results in low-double-digit total investment returns if the stock&#39;s valuation remains constant.</p><h2>3. UnitedHealth Group</h2><p>Health insurance company <b>UnitedHealth Group</b> (NYSE:UNH) is one of the world&#39;s largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.</p><p>The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It&#39;s likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.</p><p>UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company&#39;s dividend offers a yield of 1.1% as an added bonus for shareholders.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-18 22:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4548":"巴美列捷福持仓","ABT":"雅培","BK4532":"文艺复兴科技持仓","UNH":"联合健康","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","BNTX":"BioNTech SE","BK4082":"医疗保健设备","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4154":"管理型保健护理","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4581":"高盛持仓"},"source_url":"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2220711686","content_text":"The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you're close to retirement.Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.1. PfizerPharmaceutical giant Pfizer (NYSE:PFE) has benefited from COVID-19 as one of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management's 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer's 2021 sales.Image source: Getty Images.However, the important part of this isn't the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer's nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer's growth efforts, even after its revenues from COVID-19 treatments fade.Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer's large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.2. Abbott LabsThe healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as AbbVie almost a decade ago. Today, Abbott Labs (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company's revenue growth has picked up, growing more than 15% annually over the past five years.This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today's share price, which results in low-double-digit total investment returns if the stock's valuation remains constant.3. UnitedHealth GroupHealth insurance company UnitedHealth Group (NYSE:UNH) is one of the world's largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It's likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company's dividend offers a yield of 1.1% as an added bonus for shareholders.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9035548752,"gmtCreate":1647647701947,"gmtModify":1676534254348,"author":{"id":"3586939439858903","authorId":"3586939439858903","name":"ASMH","avatar":"https://static.tigerbbs.com/c8c22c3127769d9bb7b4e8d291d98433","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586939439858903","authorIdStr":"3586939439858903"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9035548752","repostId":2220711686,"repostType":4,"repost":{"id":"2220711686","pubTimestamp":1647614760,"share":"https://ttm.financial/m/news/2220711686?lang=&edition=fundamental","pubTime":"2022-03-18 22:46","market":"us","language":"en","title":"Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2220711686","media":"Motley Fool","summary":"As you approach your golden years, these companies could deliver the stability and growth that you need.","content":"<html><head></head><body><p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it&#39;s important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you&#39;re close to retirement.</p><p>Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.</p><h2>1. Pfizer</h2><p>Pharmaceutical giant <b>Pfizer</b> (NYSE:PFE) has benefited from COVID-19 as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management&#39;s 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer&#39;s 2021 sales.</p><p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F669475%2Fgettyimages-1316488076.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/><span>Image source: Getty Images.</span></p><p>However, the important part of this isn&#39;t the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer&#39;s nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer&#39;s growth efforts, even after its revenues from COVID-19 treatments fade.</p><p>Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer&#39;s large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.</p><h2>2. Abbott Labs</h2><p>The healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as <b>AbbVie</b> almost a decade ago. Today, <b>Abbott Labs</b> (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.</p><p>Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company&#39;s revenue growth has picked up, growing more than 15% annually over the past five years.</p><p>This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today&#39;s share price, which results in low-double-digit total investment returns if the stock&#39;s valuation remains constant.</p><h2>3. UnitedHealth Group</h2><p>Health insurance company <b>UnitedHealth Group</b> (NYSE:UNH) is one of the world&#39;s largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.</p><p>The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It&#39;s likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.</p><p>UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company&#39;s dividend offers a yield of 1.1% as an added bonus for shareholders.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-18 22:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4548":"巴美列捷福持仓","ABT":"雅培","BK4532":"文艺复兴科技持仓","UNH":"联合健康","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","BNTX":"BioNTech SE","BK4082":"医疗保健设备","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4154":"管理型保健护理","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4581":"高盛持仓"},"source_url":"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2220711686","content_text":"The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you're close to retirement.Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.1. PfizerPharmaceutical giant Pfizer (NYSE:PFE) has benefited from COVID-19 as one of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management's 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer's 2021 sales.Image source: Getty Images.However, the important part of this isn't the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer's nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer's growth efforts, even after its revenues from COVID-19 treatments fade.Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer's large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.2. Abbott LabsThe healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as AbbVie almost a decade ago. Today, Abbott Labs (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company's revenue growth has picked up, growing more than 15% annually over the past five years.This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today's share price, which results in low-double-digit total investment returns if the stock's valuation remains constant.3. UnitedHealth GroupHealth insurance company UnitedHealth Group (NYSE:UNH) is one of the world's largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It's likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company's dividend offers a yield of 1.1% as an added bonus for shareholders.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9035549713,"gmtCreate":1647647335302,"gmtModify":1676534254329,"author":{"id":"4099055228687120","authorId":"4099055228687120","name":"xuero","avatar":"https://static.tigerbbs.com/043271093c85fc090b9b3f3a6e36cec5","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"4099055228687120","authorIdStr":"4099055228687120"},"htmlText":"I don't think risking 450k (150k each) to make 550k (total 1 mil) in 10 years is attractive at all. Did I understand wrongly?&nbsp;[Thinking]&nbsp;[Doubt]&nbsp;[Glance]&nbsp;[Smug]&nbsp;[Speechless]&nbsp;","listText":"I don't think risking 450k (150k each) to make 550k (total 1 mil) in 10 years is attractive at all. Did I understand wrongly?&nbsp;[Thinking]&nbsp;[Doubt]&nbsp;[Glance]&nbsp;[Smug]&nbsp;[Speechless]&nbsp;","text":"I don't think risking 450k (150k each) to make 550k (total 1 mil) in 10 years is attractive at all. Did I understand wrongly? [Thinking] [Doubt] [Glance] [Smug] [Speechless]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9035549713","repostId":2220711686,"repostType":4,"repost":{"id":"2220711686","pubTimestamp":1647614760,"share":"https://ttm.financial/m/news/2220711686?lang=&edition=fundamental","pubTime":"2022-03-18 22:46","market":"us","language":"en","title":"Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2220711686","media":"Motley Fool","summary":"As you approach your golden years, these companies could deliver the stability and growth that you need.","content":"<html><head></head><body><p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it&#39;s important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you&#39;re close to retirement.</p><p>Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.</p><h2>1. Pfizer</h2><p>Pharmaceutical giant <b>Pfizer</b> (NYSE:PFE) has benefited from COVID-19 as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management&#39;s 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer&#39;s 2021 sales.</p><p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F669475%2Fgettyimages-1316488076.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/><span>Image source: Getty Images.</span></p><p>However, the important part of this isn&#39;t the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer&#39;s nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer&#39;s growth efforts, even after its revenues from COVID-19 treatments fade.</p><p>Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer&#39;s large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.</p><h2>2. Abbott Labs</h2><p>The healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as <b>AbbVie</b> almost a decade ago. Today, <b>Abbott Labs</b> (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.</p><p>Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company&#39;s revenue growth has picked up, growing more than 15% annually over the past five years.</p><p>This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today&#39;s share price, which results in low-double-digit total investment returns if the stock&#39;s valuation remains constant.</p><h2>3. UnitedHealth Group</h2><p>Health insurance company <b>UnitedHealth Group</b> (NYSE:UNH) is one of the world&#39;s largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.</p><p>The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It&#39;s likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.</p><p>UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company&#39;s dividend offers a yield of 1.1% as an added bonus for shareholders.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-18 22:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4548":"巴美列捷福持仓","ABT":"雅培","BK4532":"文艺复兴科技持仓","UNH":"联合健康","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","BK4535":"淡马锡持仓","BNTX":"BioNTech SE","BK4082":"医疗保健设备","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4154":"管理型保健护理","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4581":"高盛持仓"},"source_url":"https://www.fool.com/investing/2022/03/17/want-1-million-in-retirement-invest-150000-in-thes/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2220711686","content_text":"The last decade before retirement is when many people put their wealth-building efforts into overdrive to get ready for their golden years. However, it's important to manage your risk carefully, as a catastrophic misstep could be hard to recover from when you're close to retirement.Investing a large sum like $150,000 into each of these three healthcare names as part of a diversified portfolio could deliver enough growth to double or more over the coming decade, helping you secure the nest egg you need to retire comfortably. Remember, managing risk can be just as important as generating returns, especially as you approach retirement.1. PfizerPharmaceutical giant Pfizer (NYSE:PFE) has benefited from COVID-19 as one of the leading vaccine manufacturers. Its vaccine Comirnaty and oral COVID-19 pill Paxlovid are expected to contribute $32 billion and $22 billion, respectively, to management's 2022 revenue guidance of between $98 billion and $102 billion. This figure would represent a 26% increase over Pfizer's 2021 sales.Image source: Getty Images.However, the important part of this isn't the near-term windfall of cash but what it means for the company over the long term. Pharmaceutical companies live and die by their product pipelines, and Pfizer's nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer's growth efforts, even after its revenues from COVID-19 treatments fade.Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer's large balance sheet should help the company fund its growth beyond that. Investors also get the benefit of a dividend that yields 3.2%, so the ingredients are there for total returns of 10% or higher per year, more than enough to double an investment over the next decade.2. Abbott LabsThe healthcare conglomerate has gone through some changes since spinning its pharmaceutical business out as AbbVie almost a decade ago. Today, Abbott Labs (NYSE:ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets.Abbott is positioned to cater especially to the cardiology and diabetes fields, which are both fast-growing; heart disease and diabetes are among the most prevalent health conditions in the population. Abbott sells devices for them, including pacemakers, catheters, stents for cardiovascular applications, and a glucose monitoring system for diabetes patients. The company's revenue growth has picked up, growing more than 15% annually over the past five years.This renewed growth could set the company to perform well over the next decade. Analysts believe Abbott will grow EPS an average of 10% annually over the next three to five years. Abbott also has a storied dividend history that goes back decades before its split with AbbVie. Investors can get a dividend yield of 1.6% on today's share price, which results in low-double-digit total investment returns if the stock's valuation remains constant.3. UnitedHealth GroupHealth insurance company UnitedHealth Group (NYSE:UNH) is one of the world's largest healthcare businesses, providing health insurance and other care services to more than 146 million people in the United States and around the world. Its insurance business is complemented by Optum, which provides healthcare products and services directly to consumers.The company has done $285 billion in revenue over the past 12 months, and its $465 billion market cap makes it a core pillar of the healthcare industry as we know it. U.S. healthcare spending hit $4.1 trillion in 2020, increasing 9.7% over the previous year. It's likely that a lot of this growth was driven by COVID-19, but the prevalence of chronic conditions amid the population could drive growth for years to come. They account for more than $1 trillion in spending alone.UnitedHealth Group just wrapped up its fiscal 2021 year, growing revenue 12% year over year, driven by double-digit growth in both of its insurance and Optum business segments. Analysts expect EPS to grow an average of nearly 15% annually over the next three to five years, giving investors all the ammunition they need to double their money over the next decade if this is accurate. The company's dividend offers a yield of 1.1% as an added bonus for shareholders.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":487,"commentSize":61,"repostSize":0,"favoriteSize":3,"likeStatus":false,"favoriteStatus":false}}